Sienna Biopharmaceuticals, Inc.
SNNAQ
$0.00
$0.000.00%
OTC PK
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.02M | 2.94M | 3.95M | 4.30M | 5.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.84M | 8.03M | 10.44M | 15.07M | 17.28M |
| Operating Income | -8.84M | -8.03M | -10.44M | -15.07M | -17.28M |
| Income Before Tax | -8.59M | -8.26M | -16.38M | -19.34M | -16.79M |
| Income Tax Expenses | -4.62M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.97M | -8.26M | -16.38M | -19.34M | -16.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.97M | -8.26M | -16.38M | -19.34M | -16.79M |
| EBIT | -8.84M | -8.03M | -10.44M | -15.07M | -17.28M |
| EBITDA | -8.81M | -7.99M | -10.40M | -15.03M | -17.25M |
| EPS Basic | -0.13 | -0.27 | -0.67 | -0.93 | -0.82 |
| Normalized Basic EPS | -0.19 | -0.18 | -0.28 | -0.44 | -0.53 |
| EPS Diluted | -0.13 | -0.27 | -0.67 | -0.93 | -0.82 |
| Normalized Diluted EPS | -0.19 | -0.18 | -0.28 | -0.44 | -0.53 |
| Average Basic Shares Outstanding | 30.73M | 30.35M | 24.61M | 20.81M | 20.47M |
| Average Diluted Shares Outstanding | 30.73M | 30.35M | 24.61M | 20.81M | 20.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |